Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

NCT ID: NCT01929031

Last Updated: 2016-11-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 562 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2014-03-31

Brief Summary

The primary objective of this study is to compare the efficacy of a combination product containing ibuprofen 400 mg and caffeine 100 mg versus either ingredient alone as well as placebo for the treatment of post-surgical dental pain over an eight-hour period followed by a single dose of study medication (study stage 1). A secondary objective is to evaluate efficacy of multiple doses of the combination in comparison to ibuprofen alone over a 5-day post-surgical period (study stage 2).

Conditions

Pain, Postoperative; Tooth Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Caffeine-Ibuprofen

Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator

Group Type: OTHER

ibuprofen

Intervention Type: DRUG

tablet

caffeine

Intervention Type: DRUG

tablet

Placebo-Ibuprofen/Caffeine

Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental

Group Type: OTHER

ibuprofen + caffeine

Intervention Type: DRUG

FDC tablet

placebo

Intervention Type: DRUG

tablet

Ibuprofen/Caffeine-Ibuprofen/Caffeine

Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental

Group Type: OTHER

ibuprofen + caffeine

Intervention Type: DRUG

Fixed Dose Combination (FDC) tablet

Ibuprofen-Ibuprofen

Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator

Group Type: OTHER

ibuprofen

Intervention Type: DRUG

tablet.

Caffeine-Ibuprofen/Caffeine

Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental

Group Type: OTHER

caffeine

Intervention Type: DRUG

tablet

ibuprofen + caffeine

Intervention Type: DRUG

FDC tablet

Placebo-Ibuprofen

Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator

Group Type: OTHER

placebo

Intervention Type: DRUG

tablet

ibuprofen

Intervention Type: DRUG

tablet

Interventions

ibuprofen + caffeine

FDC tablet

Intervention Type: DRUG

ibuprofen

tablet.

Intervention Type: DRUG

ibuprofen

tablet

Intervention Type: DRUG

caffeine

tablet

Intervention Type: DRUG

ibuprofen + caffeine

Fixed Dose Combination (FDC) tablet

Intervention Type: DRUG

placebo

tablet

Intervention Type: DRUG

placebo

tablet

Intervention Type: DRUG

caffeine

tablet

Intervention Type: DRUG

ibuprofen

tablet

Intervention Type: DRUG

ibuprofen + caffeine

FDC tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males and females 18 to 55 years of age;
• Outpatients scheduled to undergo surgical extraction of 3-4 impacted third molar(s), with a minimum of two mandibular extractions. The two mandibular third molars may be partial bony impactions or full bony impactions (as long as the trauma rating is not severe and the surgeons do not feel the subject will have extreme post-surgical pain) OR there may be a combination of one full bony impaction with the second mandibular being a soft tissue impaction or partial bony impaction. Maxillary third molars (or supernumerary teeth) of any type can be extracted;
• Use of only the following preoperative medication(s)/ anesthetic(s): topical benzocaine, short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide;
• Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
• Examined by the attending oral surgeon or physician and medically cleared to participate in the study;
• Scheduled to undergo a qualifying surgical procedure;
• In good general health, with a BMI of 30 or less, and have no contraindications to any of the study medications or anesthetic drugs;
• Subjects have at least a categorical pain score of moderate and a numerical rating scale (NRS) score of 5 or greater within 4.5 hours from the time of the last suture.

Exclusion Criteria

• Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, hyper- or hypothyroidism);
• Use of a prescription or non-prescription drug with which the administration of ibuprofen or any other non steroidal anti inflammatory or caffeine is contraindicated;
• Acute local infection at the time of surgery that could confound the post-surgical evaluation;
• Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, intravaginal or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
• Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
• History of alcoholism or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Subjects who are taking central nervous system or other psychotropic drugs (including St. Johns Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
• Habituation to analgesic drugs or caffeine (i.e., routine use of oral analgesics 5 or more times per week or ingestion of 4 or more caffeine-containing drinks daily); use of "high energy" drinks more than once per week;
• Use of any type of systemic corticosteroid within the past 30 days or a history of current or previous use of anabolic steroids;
• History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to acetaminophen, ibuprofen, naproxen, aspirin, celecoxib, or any other non steroidal anti inflammatory or caffeine;
• Prior use of any type of analgesic or non steroidal anti inflammatory within 5 half-lives of that drug before surgery, except for pre-anesthetic medication and anesthesia for the procedure;
• Ingestion of any caffeine-containing beverages, chocolate, or alcohol 6 hours or less before surgery;
• Has impaired liver function, e.g., serum Alanine transaminase, aspartate aminotransferase, alkaline phosphatase, or Gamma-glutamyltransferase greater than 2.5 times the upper limit of normal, or blood urea nitrogen, creatinine, or bilirubin greater than 1.5 times the upper limit of normal without a known benign explanation;
• Has known history of a positive HIV antibody test or known HIV infection;
• Has a known history of Hepatitis B or C;
• Has a clinically significant abnormal electrocardiogram (ECG) at screening as determined by the Investigator:
• Has taken an investigational product within the past 30 days;
• Has previously been entered into this study;
• The subject is a member of the study site staff either directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study or Sponsor.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

1335.1.202 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Countries

United States

References

Forderreuther S, Lampert A, Hitier S, Lange R, Weiser T. The Impact of Baseline Pain Intensity on the Analgesic Efficacy of Ibuprofen/Caffeine in Patients with Acute Postoperative Dental Pain: Post Hoc Subgroup Analysis of a Randomised Controlled Trial. Adv Ther. 2020 Jun;37(6):2976-2987. doi: 10.1007/s12325-020-01297-y. Epub 2020 Apr 24.

Reference Type: DERIVED

PMID: 32333328 (View on PubMed)

Weiser T, Richter E, Hegewisch A, Muse DD, Lange R. Efficacy and safety of a fixed-dose combination of ibuprofen and caffeine in the management of moderate to severe dental pain after third molar extraction. Eur J Pain. 2018 Jan;22(1):28-38. doi: 10.1002/ejp.1068. Epub 2017 Aug 14.

Reference Type: DERIVED

PMID: 28805281 (View on PubMed)

Other Identifiers

1335.1

Identifier Type: -

Identifier Source: org_study_id